A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis

PHASE2TerminatedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

August 29, 2011

Study Completion Date

August 29, 2011

Conditions
Primary MyelofibrosisPost-Polycythemia VeraPost-Essential Thrombocytopenia
Interventions
DRUG

Panobinostat

Panobinostat oral capsules

Trial Locations (9)

10021

New York Presbyterian Hospital - Weill Cornell Medical College, New York

30912

Medical College of Georgia, Augusta

48109

University of Michigan, Ann Arbor

55905

Mayo Clinic - Rochester, Rochester

60611

Northwestern University Feinberg School of Medicine, Chicago

85259

Mayo Clinic - Scottsdale, Scottsdale

91010

City of Hope National Medical Center, Duarte

94305

Stanford Comprehensive Cancer Center, Stanford

02115

Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY